SLN+ melanoma and adjuvant anti–PD-1 therapy—patients with and without immediate CLND
| Characteristic | No IM CLND (N=326) | With IM CLND (N=60) | Parametric p value* |
| Gender, no (%) | |||
| Female | 118 (36.2) | 23 (38.3) | 0.752 |
| Male | 208 (63.8) | 37 (61.7) | |
| Extranodal extension, no (%) | |||
| Yes | 21 (6.7) | 20 (33.3) | <0.001 |
| No | 292 (93.3) | 40 (66.7) | |
| Ulcerated primary, no (%) | |||
| Yes | 144 (48.5) | 28 (46.7) | |
| No | 153 (51.5) | 32 (53.3) | 0.797 |
| AJCC v8 stage, no (%) | |||
| IIIA | 69 (21.2) | 10 (16.7) | 0.008 |
| IIIB | 78 (23.9) | 5 (8.3) | |
| IIIC/IIID | 179 (54.9) | 45 (75) | |
| No of positive SLNs, no (%) | |||
| 1 | 90 (27.6) | 22 (36.7) | 0.155 |
| ≥2 | 236 (72.4) | 38 (63.3) | |
| SLN tumor deposit (if known) | |||
| Median ≤1 mm >1 mm | 1 mm 149 (51) 143 (49) | 4.2 mm 17 (28) 43 (72) | <0.001 |
| Primary tumor location, no (%) | |||
| Head/neck | 41 (12.6) | 9 (15) | 0.502 |
| Lower ext | 102 (31.4) | 13 (21.7) | |
| Trunk | 121 (37.2) | 26 (43.3) | |
| Upper ext | 61 (18.8) | 12 (20) | |
| Received adjuvant nodal XRT no (%) | |||
| Yes No | 1 (0.3) 325 (99.7) | 9 (15) 51 (85) | <0.001 |
| BRAF status, no (%) (if known) | |||
| Mutant | 81 (37.2) | 21 (50) | 0.119 |
| Wildtype | 137 (62.8) | 21 (50) | |
| Median age, y | 60.1 (range 18–93) | 59.5 (range 24–82) | 0.814 |
*The parametric p value is calculated by ANOVA for numerical covariates and χ2 test for categorial values.
AJCC, American Joint Committee on Cancer; ANOVA, analysis of variance; CLND, completion lymph node dissection; ext, extremity; IM, immediate; SLN, sentinel lymph node; XRT, radiation therapy.